Table 3 Facilitators of use of MgSO4 for fetal neuroprotection (N (%) responses for all responses that relate to facilitators)*
Nodes | Sub-nodes | Site visits (N = 128) | Barriers & Facilitators Survey (N = 171) |
|---|---|---|---|
Individual-level | 17 (13.3Â %) | 38 (22.2Â %) | |
 Supportive attitudes and beliefs | 4 (3.1 %) | 9 (5.3 %) | |
 Knowledge and understanding | 8 (6.3 %) | 15 (8.8 %) | |
 Early adopters/mobilizers | 1 (0.8 %) | 9 (5.3 %) | |
 Comfort/experience using MgSO4 | 4 (3.1 %) | 5 (2.9 %) | |
Institutional-level | 80 (62.5Â %) | 107 (62.6Â %) | |
 Policies and protocols | Overall | 34 (26.6 %) | 26 (15.2 %) |
 Pre-printed orders for MgSO4 use | 5 | 6 | |
 Pre-mixed bags of MgSO4 | 8 | 2 | |
 Mechanism for audit and feedback | 8 | 3 | |
 Unclassifiable | 13 | 15 | |
 Local champion/opinion leader | 8 (6.3 %) | 11 (6.4 %) | |
 Facility characteristics | Overall | 38 (29.7 %) | 70 (40.9 %) |
 Supportive institutional culture/evidence-based | 18 | 38 | |
 Patient load | 3 | 10 | |
 Human resource capacity | 5 | 4 | |
 Education and professional development | 12 | 18 | |
Social-level | 31 (24.2Â %) | 26 (15.2Â %) | |
 Patient voice/awareness | 4 (3.1 %) | 2 (1.2 %) | |
 Knowledge translation | 17 (13.3 %) | 5 (2.9 %) | |
 Community support | 2 (1.6 %) | 0 | |
 Communication and collaboration | 8 (6.3 %) | 19 (11.1 %) | |